株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

中国の医薬品製造業

China pharmaceutical manufacturing industry, 2016

発行 Reports From China 商品コード 243613
出版日 ページ情報 英文 184 Pages
納期: お問合せ
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。

ご注意:当報告書は原文が中国語のため、英訳が必要となる場合があります。納期については、当社までお問合せ下さい。

Back to Top
中国の医薬品製造業 China pharmaceutical manufacturing industry, 2016
出版日: 2016年03月04日 ページ情報: 英文 184 Pages
概要

当レポートでは、中国における医薬品の製造業の最新動向について調査し、国際・国内市場の動向や、産業の実態・実績(企業数、資産額、総生産額など)、競争環境、主要企業の概要(基本情報、経営状況、資産・負債、支出・費用)、投資環境、技術開発動向、発展動向予測などについて分析しています。

第1部 産業の概況

第1章 医薬品製造業の定義と発展

  • 市場と主力製品の定義
  • 産業の主な特徴と発展の歴史

第2章 マクロ経済環境とその影響

  • 現在のマクロ経済の発展と傾向
  • 最新の産業政策と関連法規・規制
  • 上流/下流過程産業の発展状況

第3章 国際市場分析

  • 国際市場の現在の発展状況
  • 主要国・地域の発展水準
  • 国際市場の動向の分析

第4章 中国国内市場分析

  • 国内市場の現在の発展状況
  • 国内市場の動向
  • 主要産業および各産業の市場発展状況

第2部 基本的事項

第5章 規模の分析

  • 企業総数
  • 赤字の企業数
  • 産業全体の赤字額
  • 従業員数

第6章 資産の分析

  • 資産総額
  • 固定資産総額
  • 流動資産総額

第3部 経営状況

第7章 総生産額の分析

  • 総生産額
  • 地域別総生産額
  • 上位20社の比較(総生産額ベース)

第8章 販売収益の分析

  • 販売収益総額
  • 地域別販売収益額
  • 上位20社の比較(販売収益ベース)

第9章 総利益の分析

  • 総利益額
  • 地域別総利益額
  • 上位20社の比較(総利益額ベース)

第10章 輸出入の分析

  • 輸出/輸入の月次総額
  • 顧客別・相手国別の輸出入額
  • 輸出品/輸入品の製品分野別の内訳

第4部 競争環境

第11章 競争環境の分析

  • 各地域の市場の競争環境
  • 各企業の市場シェアの比較

第12章 主要企業の競争力の比較分析

  • 主要企業の総資産の比較分析
  • 主要企業の従業員数の比較分析
  • 主要企業の年間収益の比較分析
  • 主要企業の輸出額の比較分析
  • 主要企業の総利益額の比較分析
  • 主要企業の全体的競争力の比較分析

第5部 主要企業

第13章 主要企業の比較分析

  • Yangtze River Pharmaceutical Group Co., Ltd
  • Harbin Pharmaceutical Group Co., Ltd
  • Jilin Xiuzheng Pharmaceutical Group Co., Ltd
  • CSPC Pharmaceutical Group Limited
  • Weigao Holding Company Limited
  • Northeast Pharmaceutical Group Co., Ltd
  • Bayer HealthCare Co., Ltd
  • North China Pharmaceutical Group Corp.
  • Xinxiang Liuzhuang Agriculture- Industry-Commerce United Company
  • Xi'an Janssen Pharmaceutical Ltd
  • Henan Caixin Group Co., Ltd
  • Yishui Dadi Corn Developing Co., Ltd
  • Pfizer Pharmaceuticals Limited
  • Novo Nordisk (China) Pharmaceuticals Co., Ltd
  • Tianjin Zhongxin Pharmaceutical Group Corporation Limited
  • Reyoung Pharmaceutical Co., Ltd
  • Shijiazhuang PharmaGroup Zhongrun Pharmaceutical (Inner Mongolia) Co., ltd
  • Shanghai Roche Pharmaceuticals Limited
  • Zhejiang Medicine Co., Ltd Xinchang Pharmaceutical Factory
  • Huiren Group Co., Ltd

第6章 事業戦略

第14章 産業発展上のボトルネックと解決策

  • 産業発展上のボトルネック
  • 解決策

第15章 企業の発展戦略の分析と提言

  • 企業の事業戦略の分析と提言
  • 企業のマーケティング戦略の分析と提言

第7部 市場投資

第16章 投資活動係数と投資収益の比較・分析

  • 産業活動係数の比較分析
  • 投資収益の比較・分析

第17章 投資環境・投資リスクの分析

  • 投資環境分析
  • 投資リスク分析
  • 投資に関する提言

第8部 技術

第18章 最新技術適用の現状と傾向

  • 最新技術適用の現状
  • 技術開発の傾向

第9部 発展と動向

第19章 発展動向と操業能力の予測

  • 発展動向
  • 操業能力予測
  • 見解と提言

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 19536

Pharmaceutical Manufacturing Industry refers to the procedure during which after physical or chemical change raw materials turn into new pharmaceutical products including common traditional Chinese medicine, western medicine and veterinary drugs consisting of pharmaceutical raw materials and hygienic materials.

The manufacturing of active compounds made from chemicals includes: Manufacturing of such active compounds with chemicals as antibiotics, endocrine products, essential vitamins, sulfo-drugs, salicylates, glucose and alkaloid drug substance; chemical pure sugar. Excluding: the manufacturing of blood and plasma and other blood products that are categorized as the manufacturing of biological and biochemical products (code: 2760).

Chemical pharmaceutical manufacturing includes: tablet, injection, capsule, potion, cream, powder, solvent and so on; radiopharmaceuticals. Excluding: the manufacturing of Chinese patent medicine (code: 2740); the manufacturing of veterinary drugs (code: 2750); the manufacturing of biological products and biochemical drugs (code: 2760).

Chinese herbal pieces processing includes: a variety of Chinese herbal medicines made through the manufacturing and formation of Chinese medicine materials; other manufacturing of the extraction of traditional Chinese medicine.

Chinese patent medicine manufacturing includes: honeyed pill, water pills, granules, syrup, plaster, etc. made by the production method of traditional Chinese medicine; tablet, injection, capsule, oral liquid, etc. made by the method of modern pharmaceutical production of traditional Chinese medicine; specially curative medicinal liquor.

Veterinary drug manufacturing includes: animal chemicals, animal antibiotics, animal vaccines, Chinese herbal medicine; feed drugs, aquaculture drugs, etc. Excluding the production of feed additives (growth promoting agent), which is categorized into food and feed additives manufacturing (code: 1494).

The manufacturing of biological and biochemical product includes: genes, cells, enzymes, fermentation engineering drugs, genetic engineering vaccine, new vaccine, vaccine; medicinal amino acids, antibiotics, vitamin, micro ecological preparation medicine; blood products and substitutes; diagnostic reagents: blood grouping reagents, X-ray contrast agent, patient diagnosis reagent; biochemical medicines made of animal liver.

The manufacturing of hygienic materials and medical products includes: surgical dressings, pharmaceutical packing: sticking plaster, absorbent cotton, bandages, etc.; curing materials, biological materials, dental filling materials, orthodontic materials, impression materials, abrasive materials used in treatment of dental adhesives; sterile absorbable hemostatic materials used in surgery and dentistry; bandages, gut and other surgical suture for fracture; gelatin medicinal capsules; the manufacturing of medical polymer materials and products. Excluding: medical gauze manufacturing, listed in cotton and chemical fiber textile processing (code: 1711 ); the manufacturing of glass ampoules, vials and other medical glassware, listed glass manufacturing ( code: 3144 ); aluminum foil production, listed in the production of other daily metal products (code: 3489); production of pharmaceutical packaging composite film, listed in the production of plastic film ( code: 3010 ); the manufacturing of dentures, artificial organs and other provided by dentists, listed in the production of prostheses, artificial organs and implantable device ( code: 3686); medical rubber products, listed in 2920, rubber products manufacturing ,in more detail, the manufacturing of rubber sheet, pipe, tape (code: 2920) and the manufacturing of daily and medical rubber products medical (code: 2950); Plastic products manufacturing, listed in manufacturing of other plastic products (code: 3090).

For the past few years, China has promulgated many reform measures. Those closely relating to the pharmaceutical industry mainly included: basic medical insurance system, drug classification management, GMP certification system, purchase of drugs by centralized bidding, drug price reduction and export rebate rate reduction.

In the first half year of 2015, the overall growth rate of the pharmaceutical industry dropped. Bio-pharmaceutical (including biological detection), medical instrument and medical service enterprises were almost all expected to grow. The rapid development of such three kinds of enterprises shows that China's pharmaceutical industry is making structural adjustment based on the support of policies. The whole industry has an obvious development trend towards technology improvement.

The first future trend of the pharmaceutical industry is: the industrial gross will continue to grow, and present size is huge at a multi trillion level.

The second future trend of the pharmaceutical industry is industry integration. Integration of the circulation in the field will be intensified to realize concentration rapidly. The market survey analysis report on pharmaceutical industry shows that in the United States, three of the circulation enterprises account for 96% of the drug market. China has tens of thousands of circulation enterprises most of which will be integrated sooner or later.

The third future trend of pharmaceutical industry: Industrial upgrading. The first is the upgrading of products, such as prescription, technology, standard, and dosage form etc.

China pharmaceutical manufacturing industry, 2016 provides a complete set of the industry data, import/export data, the top 20 companies' database, and 5 years of forecast.

China pharmaceutical manufacturing industry, 2016 is valuable for anyone who wants to invest in the pharmaceutical manufacturing industry, to get Chinese investments; to import into China or export from China, to build factories and take advantage of lower costs in China, to partner with one of the key Chinese corporations, to get market shares as China is boosting its domestic needs; to forecast the future of the world economy as China is leading the way; or to compete in the segment. The report provides the whole set of the industry data, in-depth analysis and detailed insight into the pharmaceutical manufacturing industry, market drivers, key enterprises and their strategies, as well as technologies and investment status, risks and trends.

Data sources: Governmental statistics organizations, market research (monitoring) centers, industry associations and institutions, import and export statistics organizations, and others.

There are 123 figures and tables in the report.

Report format: PDF

Knowledge is power. If you want to invest in, import into/from, partner with, or compete against any of the companies in this field, then China pharmaceutical manufacturing industry, 2016 is required reading.

This report can be delivered immediately.

Table of Contents

Part I: Industry Overview

1. Definition and development of pharmaceutical manufacturing industry

  • 1.1. Definition of the industry and its core products
    • 1.1.1. Definition of the industry
    • 1.1.2. Core products
  • 1.2. Main characteristics of the industry and a history of its development
    • 1.2.1. Major characteristics of the industry
    • 1.2.2. Course of industrial development

2. Macro environment and impact analysis of pharmaceutical manufacturing industry

  • 2.1. Current macroeconomic developments and trends
    • 2.1.1. China macroeconomic operating environment: 2014
    • 2.1.2. Recommendation on related policies
  • 2.2. Latest industry policies and related laws and regulations
  • 2.3. Development of Upstream and Downstream Industries
    • 2.3.1. Upstream industries
    • 2.3.2. Downstream industries

3. International market analysis of pharmaceutical manufacturing industry

  • 3.1. Current development of its international market
  • 3.2. Levels of development in key countries and regions
    • 3.2.1. United States
    • 3.2.2. United Kingdom

4. Domestic market analysis of pharmaceutical manufacturing industry

  • 4.1. Current development of its domestic market
  • 4.2. Trends in the domestic market

Part 2: Basic indices

5. Size analysis of pharmaceutical manufacturing industry during 2008-2014

  • 5.1. Enterprise number status: 2008-2014
  • 5.2. Number of loss- making enterprises: 2008-2014
  • 5.3. Total loss of the industry: 2008- 2014
  • 5.4. Number of employees: 2008-2014

6. Asset analysis of pharmaceutical manufacturing industry during 2008-2014

  • 6.1. Gross assets of the industry: 2008-2014
  • 6.2. Status of fixed assets: 2008-2014
  • 6.3. Current assets: 2007-2013

Part 3: Economic Operation

7. Gross industrial output value analysis of pharmaceutical manufacturing industry during 2008-2014

  • 7.1. Gross industrial output value: 2008-2014
    • 7.1.1. Overview
    • 7.1.2. By scale
    • 7.1.3. By ownership
  • 7.2. Distribution of gross industrial output value by region: 2014

8. Sales revenue analysis of pharmaceutical manufacturing industry during 2008-2014

  • 8.1. Total industry sales revenue: 2008-2014
    • 8.1.1. Overview
    • 8.1.2. By scale
    • 8.1.3. By ownership
  • 8.2. Distribution of sales revenue by region in 2014

9. Total profits analysis of pharmaceutical manufacturing industry during 2008-2014

  • 9.1. Gross profit analysis: 2008-2014
    • 9.1.1. Overview
    • 9.1.2. By scale
    • 9.1.3. By ownership
  • 9.2. Distribution of total profits by region in 2014

10. Import and export analysis of pharmaceutical manufacturing industry in 2014

  • 10.1. Total import and export analysis of the pharmaceutical manufacturing industry in 2014
  • 10.2. Import and export country analysis of the pharmaceutical manufacturing industry in 2014
  • 10.3. Import and export customs analysis of the pharmaceutical manufacturing industry in 2014
  • 10.4. Import and export region analysis of the pharmaceutical manufacturing industry in 2014

Part 4: Competitive landscape

11. Competitive landscape analysis of pharmaceutical manufacturing industry

  • 11.1. Competitive landscape in the regional markets
  • 11.2. Market share of enterprises in the industry

12. Comparative analysis on the competitiveness of key enterprises in pharmaceutical manufacturing industry

  • 12.1. Comparison for total assets of key enterprises
  • 12.2. Comparison of the number of employees in the key enterprises in the industry
  • 12.3. Comparison for annual operational revenue of key enterprises
  • 12.4. Comparison for export delivery value of key enterprises
  • 12.5. Comparison for total profits of key enterprises
  • 12.6. Comparison for competitiveness of key enterprises

Part 5: Key Enterprises

13. Comparative analysis on the economic indicators of key enterprises in pharmaceutical manufacturing industry

  • 13.1. Yangtze River Pharmaceutical Group Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.2. Harbin Pharmaceutical Group Co., Ltd
    • A Basic information
    • B Analysis of enterprise' business operation
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.3. Jilin Xiuzheng Pharmaceutical Group Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.4. CSPC Pharmaceutical Group Limited
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.5. Weigao Holding Company Limited
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.6. Northeast Pharmaceutical Group Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.7. Bayer HealthCare Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.8. North China Pharmaceutical Group Corp.
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.9. Xinxiang Liuzhuang Agriculture- Industry-Commerce United Company
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.10. Xi'an Janssen Pharmaceutical Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.11. Henan Caixin Group Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.12. Yishui Dadi Corn Developing Co., Ltd
    • A Basic information
    • B Analysis of enterprise' business operation
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.13. Pfizer Pharmaceuticals Limited
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.14. Novo Nordisk (China) Pharmaceuticals Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.15. Tianjin Zhongxin Pharmaceutical Group Corporation Limited
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.16. Reyoung Pharmaceutical Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.17. Shijiazhuang PharmaGroup Zhongrun Pharmaceutical (Inner Mongolia) Co., ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.18. Shanghai Roche Pharmaceuticals Limited
    • A Basic information
    • B Analysis of enterprise' business operation
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.19. Zhejiang Medicine Co., Ltd Xinchang Pharmaceutical Factory
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis
  • 13.20. Huiren Group Co., Ltd
    • A Basic information
    • B Operating status analysis
    • C Assets and liabilities analysis
    • D Operating expense and cost analysis

Party 6: Operational Strategies

14. Development bottlenecks of the pharmaceutical manufacturing industry and counter strategies

  • 14.1. Development bottleneck of the industry
  • 14.2. Coping strategies of the industry

Part 7: Market Investment

15. Comparison and analysis of investment activity coefficients and investment returns of the pharmaceutical manufacturing industry

  • 15.1. Activity coefficient comparison and analysis of the industry
    • 15.1.1. Related industry activity coefficient comparison in 2014
    • 15.1.2. Activity coefficient of the industry: 2008-2014
    • 15.1.3. Views
  • 15.2. Investment return comparison and analysis of the industry
    • 15.2.1. Comparison of rate of return on investment in related industry: 2014
    • 15.2.2. Analysis on industry rate of return from investment: 2008-2014
    • 15.2.3. Views

16. Analysis of investment environment and investment risks of the pharmaceutical manufacturing industry

  • 16.1. Investment environment of the industry
    • 16.1.1. Financial barriers
    • 16.1.2. Technical barriers
    • 16.1.3. Patent barriers
  • 16.2. Investment risks of the industry
    • 16.2.1. Cyclical risks with new drug R&D
    • 16.2.2. Technological risks with new drug R&D
    • 16.2.3. Risks with industrial qualification and approval
  • 16.3. Investment recommendations

Part 8: Processes and technologies

17. Current situation and trends of the newest technology applications in the pharmaceutical manufacturing industry

  • 17.1. Application of the latest technologies in the industry
  • 17.2. Technological development trend in the industry

Part 9: Development Trends

18. Development trends and operating capability forecast of the pharmaceutical manufacturing industry

  • 18.1. Development trend of the industry
  • 18.2. Industry operating capability forecast: 2015-2019
    • 18.2.1. Total assets forecast: 2015-2019
    • 18.2.2. Total industrial output value forecast of the industry: 2015-2019
    • 18.2.3. Sales revenue forecast: 2015-2019
    • 18.2.4. Total revenue forecast: 2015-2019
Back to Top